Free Trial

Grace Therapeutics (GRCE) Competitors

Grace Therapeutics logo
$3.29 -0.10 (-2.95%)
As of 02/21/2025 03:59 PM Eastern

GRCE vs. BDTX, SAVA, TSVT, CRBU, BMEA, RENB, CHRS, SGMT, TELO, and KYTX

Should you be buying Grace Therapeutics stock or one of its competitors? The main competitors of Grace Therapeutics include Black Diamond Therapeutics (BDTX), Cassava Sciences (SAVA), 2seventy bio (TSVT), Caribou Biosciences (CRBU), Biomea Fusion (BMEA), Renovaro (RENB), Coherus BioSciences (CHRS), Sagimet Biosciences (SGMT), Telomir Pharmaceuticals (TELO), and Kyverna Therapeutics (KYTX). These companies are all part of the "pharmaceutical products" industry.

Grace Therapeutics vs.

Grace Therapeutics (NASDAQ:GRCE) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, community ranking, valuation and profitability.

Grace Therapeutics is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Grace TherapeuticsN/AN/A-$12.85M-$1.16-2.84
Black Diamond TherapeuticsN/AN/A-$82.44M-$1.33-1.62

Grace Therapeutics currently has a consensus price target of $12.00, indicating a potential upside of 264.74%. Black Diamond Therapeutics has a consensus price target of $15.50, indicating a potential upside of 617.59%. Given Black Diamond Therapeutics' higher possible upside, analysts plainly believe Black Diamond Therapeutics is more favorable than Grace Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Grace Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Black Diamond Therapeutics
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

6.1% of Grace Therapeutics shares are owned by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 13.5% of Grace Therapeutics shares are owned by insiders. Comparatively, 8.9% of Black Diamond Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Grace Therapeutics has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500. Comparatively, Black Diamond Therapeutics has a beta of 2.51, meaning that its stock price is 151% more volatile than the S&P 500.

Black Diamond Therapeutics received 50 more outperform votes than Grace Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Grace Therapeutics an outperform vote while only 69.86% of users gave Black Diamond Therapeutics an outperform vote.

CompanyUnderperformOutperform
Grace TherapeuticsOutperform Votes
1
100.00%
Underperform Votes
No Votes
Black Diamond TherapeuticsOutperform Votes
51
69.86%
Underperform Votes
22
30.14%

Grace Therapeutics' return on equity of -20.10% beat Black Diamond Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Grace TherapeuticsN/A -20.10% -17.10%
Black Diamond Therapeutics N/A -68.08%-49.65%

In the previous week, Grace Therapeutics had 5 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 7 mentions for Grace Therapeutics and 2 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.46 beat Grace Therapeutics' score of 1.14 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Grace Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Black Diamond Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Grace Therapeutics and Black Diamond Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Grace Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GRCE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GRCE vs. The Competition

MetricGrace TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$34.37M$7.06B$5.84B$9.14B
Dividend YieldN/A2.75%4.75%3.85%
P/E Ratio-2.845.7326.0419.11
Price / SalesN/A306.03447.4676.36
Price / CashN/A65.6738.0134.83
Price / Book0.646.717.644.62
Net Income-$12.85M$138.33M$3.18B$245.85M
7 Day Performance-4.64%-2.63%-2.00%-2.61%
1 Month Performance-15.86%-2.33%-0.44%-2.14%
1 Year PerformanceN/A-5.33%16.44%12.98%

Grace Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GRCE
Grace Therapeutics
2.6 of 5 stars
$3.29
-2.9%
$12.00
+264.7%
N/A$34.37MN/A-2.84N/AAnalyst Forecast
Analyst Revision
News Coverage
Gap Down
BDTX
Black Diamond Therapeutics
3.3793 of 5 stars
$2.37
+3.9%
$15.50
+554.0%
-53.7%$134.10MN/A-1.7890Short Interest ↓
Positive News
SAVA
Cassava Sciences
3.7747 of 5 stars
$2.78
+8.2%
$111.50
+3,910.8%
-88.5%$133.75MN/A-2.0130Gap Up
TSVT
2seventy bio
2.1861 of 5 stars
$2.57
+7.5%
$7.20
+180.2%
-53.2%$132.59M$100.39M-1.38440Analyst Forecast
News Coverage
CRBU
Caribou Biosciences
3.1342 of 5 stars
$1.43
+0.7%
$10.33
+622.6%
-80.8%$129.49M$34.48M-0.87100
BMEA
Biomea Fusion
3.3309 of 5 stars
$3.57
-0.6%
$39.36
+1,002.6%
-77.4%$129.38MN/A-0.8950Positive News
RENB
Renovaro
0.7629 of 5 stars
$0.86
+5.6%
N/A-61.1%$129.21MN/A-0.9020Earnings Report
News Coverage
Gap Up
CHRS
Coherus BioSciences
3.6681 of 5 stars
$1.10
-1.8%
$5.38
+388.6%
-56.9%$127.48M$257.24M-13.75330
SGMT
Sagimet Biosciences
1.7999 of 5 stars
$4.10
+1.0%
$23.00
+461.0%
-38.9%$125.75M$2M0.008
TELO
Telomir Pharmaceuticals
2.2879 of 5 stars
$4.21
+7.4%
N/A-54.8%$125.29MN/A-7.261Analyst Forecast
News Coverage
KYTX
Kyverna Therapeutics
1.1479 of 5 stars
$2.89
-2.7%
$25.71
+789.8%
-89.9%$124.76M$7.03M0.0096

Related Companies and Tools


This page (NASDAQ:GRCE) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners